Fundraising Fox

Jeffrey M. Jonas

Investor

Partner at Cure Ventures

Boston, Massachusetts, United States

About

Partner with over two decades in CNS drug discovery and development, contributing to medicines such as Lexapro, Vyvanse and Zulresso. Previously CEO of ABIO-X and CEO/Chief Innovation Officer at Sage Therapeutics.

Experience

  1. Tortugas NeuroscieceChief Executive Officercurrent2026 β€” presentMassachusetts, United States
  2. Compass PathwaysDirectorcurrent2025 β€” presentUnited Kingdom
  3. Kenai TherapeuticsChairmancurrent2024 β€” presentUnited States
  4. Cure VenturesPartnercurrent2024 β€” present
  5. Noema PharmaChairman of the Boardcurrent2021 β€” present
  6. Karuna TherapeuticsDirector2015 β€” 2024
  7. Generation BioDirector2016 β€” 2024
  8. Sage TherapeuticsDirector2013 β€” 2023
  9. Sage TherapeuticsChief Executive Officer2013 β€” 2020Greater Boston Area
  10. ABio-XChief Executive Officer2022 β€” 2023
  11. Shire PharmaceuticalsPresident Shire Regenerative Medicine2012 β€” 2013
  12. Shire PharmaceuticalsSenior Vice President R&D - Specialty Pharma and Regenerative Medicine2011 β€” 2012
  13. Shire PharmaceuticalsSenior Vice President Research and Development2008 β€” 2011
  14. Isis PharmaceuticalsEVP2007 β€” 2008
  15. Forest LaboratoriesEVP/CMO2002 β€” 2007
  16. UpjohnChief Medical Officer/ VP Clinical Development1991 β€” 1996

Education

  1. Harvard Medical SchoolMD
  2. Amherst CollegeBA, Biology/English
  3. Harvard Medical School

Skills & more

IND2Clinical Development91Drug Development68Pharmaceutical Industry50Biotechnology44Clinical Trials38R&D37Biopharmaceuticals37Oncology21Neurology20Drug Discovery18Regulatory Affairs15
+12 moreClinical ResearchRegulatory SubmissionsLifesciencesMedical DevicesFDACROInfectious DiseasesCross-functional Team LeadershipRegenerative MedicineCTMSNeuroscienceImmunology

From Jeffrey's professional profile.

Same school

Shared employers

Colleagues at Cure Ventures